Patents by Inventor Agneta Siegbahn

Agneta Siegbahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
    Patent number: 7829529
    Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: November 9, 2010
    Assignee: Novo Nordisk Health Care A/G
    Inventors: Mirella Ezban, Lars Christian Petersen, Agneta Siegbahn
  • Use of Factor VIIa or a Tissue Factor Antagonist for Regulating Gene Expression and Cell Migration or Chemotaxis
    Publication number: 20090036378
    Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.
    Type: Application
    Filed: July 23, 2008
    Publication date: February 5, 2009
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Mirella Ezban, Lars Christian Petersen, Agneta Siegbahn
  • Methods for Modifying Cell Motility Using Factor VIIa Antagonist
    Publication number: 20070232542
    Abstract: A novel intracellular signalling activity of coagulation factor VII (FVII) in cells expressing tissue factor (TF) is described. The present invention relates to use of FVIIa or another TF agonist, or FVIIai or another TF antagonist for the preparation of a medicament for modulation of FVIIa-induced activation of the MAPK signalling pathway in a patient. Moreover the present invention relates to a method of treatment, and a method of detecting the activity of compounds, in particular drug candidates, that interact with the FVIIa mediated intracellular signalling pathway.
    Type: Application
    Filed: May 30, 2007
    Publication date: October 4, 2007
    Applicant: Novo Nordisk A/S
    Inventors: Lars Kongsbak, Niels Bergenhem, Lars Petersen, Ole Thastrup, Don Foster, Mirella Ezban, Agneta Siegbahn
  • Methods for modifying cell motility using factor VIIa antagonist
    Publication number: 20050245449
    Abstract: A novel intracellular signalling activity of coagulation factor VII (FVII) in cells expressing tissue factor (TF) is described. The present invention relates to use of FVIIa or another TF agonist, or FVIIai or another TF antagonist for the preparation of a medicament for modulation of FVIIa-induced activation of the MAPK signalling pathway in a patient. Moreover the present invention relates to a method of treatment, and a method of detecting the activity of compounds, in particular drug candidates, that interact with the FVIIa mediated intracellular signalling pathway.
    Type: Application
    Filed: July 6, 2005
    Publication date: November 3, 2005
    Applicant: Novo Nordisk, A/S
    Inventors: Lars Kongsbak, Niels Bergenhem, Lars Petersen, Ole Thastrup, Don Foster, Mirella Ezban, Agneta Siegbahn
  • Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
    Publication number: 20050239708
    Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.
    Type: Application
    Filed: June 14, 2005
    Publication date: October 27, 2005
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Mirella Ezban, Lars Petersen, Agneta Siegbahn
  • Methods for modifying cell motility using a factor VIIa antagonist
    Publication number: 20030040481
    Abstract: A novel intracellular signalling activity of coagulation factor VII (FVII) in cells expressing tissue factor (TF) is described. The present invention relates to use of FVIIa or another TF agonist, or FVIIai or another TF antagonist for the preparation of a medicament for modulation of FVIIa-induced activation of the MAPK signalling pathway in a patient. Moreover the present invention relates to a method of treatment, and a method of detecting the activity of compounds, in particular drug candidates, that interact with the FVIIa mediated intracellular signalling pathway.
    Type: Application
    Filed: September 6, 2002
    Publication date: February 27, 2003
    Inventors: Lars Kongsbak, Niels Bergenhem, Lars Christian Petersen, Ole Thastrup, Don Foster, Mirella Ezban, Agneta Siegbahn
  • Use of FVIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
    Publication number: 20020193302
    Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis. The invention also relates to the use of of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to regulation of expression of at least one gene in a cell, e.g., Cyr61 gene.
    Type: Application
    Filed: January 14, 2002
    Publication date: December 19, 2002
    Inventors: Mirella Ezban, Lars Christian Petersen, Agneta Siegbahn
  • Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
    Patent number: 6461610
    Abstract: The present invention provides methods for modifying the motility of tissue factor (TF)-expressing cells, which are carried out by contacting such cells with an effective amount of Factor VIIai Factor VIIa agonist.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: October 8, 2002
    Assignee: Novo Nordisk A/S
    Inventors: Lars Kongsbak, Niels Bergenhem, Lars Christian Petersen, Ole Thastrup, Don Foster, Mirella Ezban, Agneta Siegbahn